Biosimilars North America 2016 Conference

November 16-17, 2016 - Iselin, NJ, United States

Conference Proceedings

Standard Price

US$ 799.00

User Details



Building on previous success, we proudly announce the return of our 3rd Annual Biosimilars USA conference to New Jersey in November 2016!

It's without doubts that the biosimilars market present lucrative opportunities for pharmaceuticals and biotech companies. Over the last 12 months, market participants have witnessed revolutionary steps in the US to facilitate commercialization. While FDA has just announced the acceptance of Amgen's Biologics License Application (BLA) for ABP 501, Biocon is also set to seek US FDA approval which the addressable market is worth more than $30 billion.

It's now time for industry colleagues to act, and to act fast to seize such opportunities. The 3rd Annual Biosimilars USA meeting will update you with the latest market developments and regulatory updates to ensure you stay at the forefront of this evolving market!


Benefits of Attending

Join us today  to:
  • Hear latest regulatory updates for smooth and speedy  approval
  • Learn successful biosimilar case studies to reshape your business model
  • Dissect regional market growth opportunities - where should you go next ?
  • Network with like-minded senior experts and engage in interactive debates


Plus Two Interactive Half-Day Pre-Conference Workshops | Tuesday November 15th 2016,

A: Leveraging Successful Patient Recruitment & Retention Strategies in Biosimilars Research
Workshop Leader: Shazia Ahmad, Director, Patient & Physician Services, UBC - An Express Scripts Company
08.00 - 12.30

B: Biosimilars: Considerations for Optimizing Access and Price
Workshop Leader: Mkaya Mwamburi, Vice President, HEOR/Evidence Generation, MKTX Market Access Solutions, LLC
13.30 - 16.45

Speakers

  • Albin James Nelson, Senior Shareholder, Schwegman Lundberg Woessner
  • Andrew Simpson, Scientific Director, Orygen Biotechnologia S/A
  • Brad Jordan, Director, Regulatory Affairs and R&D Policy, Amgen Inc.
  • Cindy Cao, Executive Director & Head of US Regulatory Affairs for Biopharmaceuticals, Sandoz Inc
  • Edric Engert, SVP Biosimilars, Teva Pharmaceuticals
  • George Wyatt, Managing Director, Wyatt Health Management
  • Jianguo Yang, CEO, Abpro Corporation -- China
  • Kevin Kyumin Lee, Partner, Kim & Chang
  • L. Ross Day, R.Ph. D.P., Director of Pharmacy, Sourcing Operations, Vizient Inc.
  • Laura Perry, Director of Scientific Affairs – Cell Line Development, Abzena
  • Molly Burich, Associate Director, Public Policy of Biosimilars, Pipeline, Reimbursement , Boehringer Ingelheim Pharmaceuticals, Inc
  • Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc.
  • Robin Chadwick, Principal, Schwegman Lundberg Woessner
  • Rodeina Challand, Director, Challand Biosimilar Consulting
  • Steinar Madsen, Medical Director, Norwegian Medicines Agency
  • T. Shantha Raju, Scientific Director, Biologics Research, Janssen Pharmaceuticals, Inc.

Please fill in your name and email to receive the conference agenda of this event.


The agenda is available as PDF under dwonloads at the right side of the page.

Venue

Renaissance Woodbridge Hotel
515 US Highway 1 South, 08830
Iselin, NJ, United States

Who should attend

CEOs, Chiefs, VPs, Directors, Principals, Heads, Managers of:
  • Biosimilars/ Biobetters
  • Portfolio Management & Strategy
  • CSO
  • Alliance Management
  • Business Development
  • Regulatory Affairs
  • Commercial
  • Planning
or anyone working with Biosimilars and Biobetters from pharmaceutical, biotechs and solution providers.


Venue

Renaissance Woodbridge Hotel
515 US Highway 1 South
Iselin, New Jersey, USA
Event details
Organizer :SAE Media Group
Event type :Conference
Attendance :Physical Event
Reference :ASDE-15418